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Abstract
Melioidosis is a disease of humans caused by opportunistic infection with the soil and water bacterium Burkholderia
pseudomallei. Melioidosis can manifest as an acute, overwhelming infection or as a chronic, recurrent infection. At present, it
is not clear where B. pseudomallei resides in the mammalian host during the chronic, recurrent phase of infection. To
address this question, we developed a mouse low-dose mucosal challenge model of chronic B. pseudomallei infection and
investigated sites of bacterial persistence over 60 days. Sensitive culture techniques and selective media were used to
quantitate bacterial burden in major organs, including the gastrointestinal (GI) tract. We found that the GI tract was the
primary site of bacterial persistence during the chronic infection phase, and was the only site from which the organism
could be consistently cultured during a 60-day infection period. The organism could be repeatedly recovered from all levels
of the GI tract, and chronic infection was accompanied by sustained low-level fecal shedding. The stomach was identified as
the primary site of GI colonization as determined by fluorescent in situ hybridization. Organisms in the stomach were
associated with the gastric mucosal surface, and the propensity to colonize the gastric mucosa was observed with 4
different B. pseudomallei isolates. In contrast, B. pseudomallei organisms were present at low numbers within luminal
contents in the small and large intestine and cecum relative to the stomach. Notably, inflammatory lesions were not
detected in any GI tissue examined in chronically-infected mice. Only low-dose oral or intranasal inoculation led to GI
colonization and development of chronic infection of the spleen and liver. Thus, we concluded that in a mouse model of
melioidosis B. pseudomallei preferentially colonizes the stomach following oral inoculation, and that the chronically
colonized GI tract likely serves as a reservoir for dissemination of infection to extra-intestinal sites.
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Introduction
Burkholderia pseudomallei is a soil and water bacterium that infects
humans and other mammals in southeast Asia, northern Australia,
Brazil, and other parts of the world [1,2,3]. Infection with B.
pseudomallei can produce either acute, septicemic infections or
chronic disseminated infections with long latency periods [4,5,6,7].
Melioidosis is a particularly dangerous disease in humans because
of the rapidity with which B. pseudomallei can cause disseminated
infection and sepsis and because the organism displays high levels
of intrinsic antibiotic resistance [7,8]. These features, plus the fact
that the organism is highly persistent in the environment, have
caused B. pseudomallei to be classified as a category B select agent by
the United States Centers for Disease Control and Prevention [9].
Infection with B. pseudomallei typically develops following
exposure to bacteria in soil or water, though in 20–76% of cases
the initial source of exposure remains unknown [10,11,12,13,14].
Patients infected with B. pseudomallei may remain asymptomatic for
extended periods of time, in some cases for up to six decades
following the original exposure to the organism [4,5,10,15]. While
acute melioidosis has been relatively well-studied, much less is
known about how chronic disease develops or where the
bacterium persists during long periods of asymptomatic infection.
B. pseudomallei is well-suited for survival in the soil and moist
environments. For example, B. pseudomallei has been reported to
survive completely without nutrients in distilled water for up to 2
decades [16,17,18]. Environmental surveys have shown that B.
pseudomallei can be isolated from surface water over a wide pH
range from 2–9 [19,20]. Studies have also shown that chlorine-
treated water does not effectively kill the B. pseudomallei organism
[21,22]. Moreover, B. pseudomallei can survive in feces for up to 27
days and in urine for up to 17 days [23].
Early studies of the pathogenesis of B. pseudomallei infection,
carried out nearly a century ago using a number of different
animal challenge models, provided convincing evidence of
susceptibility to oral infection [23,24,25,26]. For example,
melioidosis could be induced by feeding B. pseudomallei-contami-
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[23,25,26]. Melioidosis was also reported in a dog and a pig that
ate meat contaminated with B. pseudomallei, and contaminated
drinking water was responsible for two outbreaks on pig farms
[27,28,29,30].
In humans, B. pseudomallei has been isolated from gastric fluids,
intestinal contents and from feces of melioidosis patients
[26,31,32]. Human infection has been attributed to ingestion of
contaminated lake or pond water, and contaminated drinking
water was blamed for two melioidosis outbreaks in Australia
[33,34,35]. Ulcers have been observed in the stomach, small
intestine and colon of human melioidosis patients, and infants
have developed melioidosis following consumption of culture
positive breast milk [6,36,37,38,39]. Moreover, B. pseudomallei has
been isolated from 26% of drinking water sources in Thailand and
Australia [40,41,42,43]. Therefore, there is mounting evidence
that B. pseudomallei infection may be contracted orally in humans
and that enteric infection may be more common than previously
appreciated.
The goal of the current study was to determine where B.
pseudomallei resided in mice during the chronic, subclinical phase of
infection and to help discern how the organism disseminated to the
spleen and liver during chronic infection. To address these
questions, we initially developed a mouse model of chronic B.
pseudomallei infection, using mucosal low-dose challenge studies in
several different strains of mice. Using selective media and
sensitive culture and detection techniques, we next investigated
potential sites of bacterial persistence during the chronic infection
phase of infection in mice.
Here we present evidence that B. pseudomallei can readily
establish persistent GI infection in mice following very low-dose
oral or intranasal inoculation. Remarkably, B. pseudomallei rapidly
and persistently infected the entire GI tract following inoculation
and appeared to preferentially colonize the gastric mucosa,
without causing any discernable GI pathology or clinical signs.
These findings suggest a possible explanation for maintenance of
asymptomatic B. pseudomallei infection in humans, but also raise a
number of new questions as to how gastric infection is maintained.
This new animal model of chronic B. pseudomallei infection should
prove useful in investigating host and pathogen factors that
regulate GI colonization and shedding and for assessing new
treatment modalities for elimination of infection.
Results
Persistent GI colonization develops following low-dose
oral inoculation with B. pseudomallei, but not B.
thailandensis
Previous studies have demonstrated infection with B. pseudomallei
following acute, high-dose oral inoculation, but effects of oral
inoculation on development of chronic infection have not been
previously assessed [23,24,25,44,45]. To investigate the ability of
B. pseudomallei to establish chronic enteric infection, we first
determined the minimal oral challenge dose of B. pseudomallei strain
1026b required to cause persistent GI colonization. To ensure that
the environmental survival traits of B. pseudomallei were not
responsible for enteric persistence, oral challenge studies were also
performed with B. thailandensis E264, a closely related but avirulent
environmental bacterium [46,47,48]. The selective medium used
to culture B. pseudomallei and B. thailandensis from GI organs in this
study was Ashdown’s medium (ASH) [49] supplemented with
norfloxacin, ampicillin and polymyxin B (NAP-A). Preliminary
studies demonstrated that growth of 25 clinical and soil B.
pseudomallei strains, and 3 B. thailandensis strains, on NAP-A medium
was equivalent when compared to growth on ASH, or LB agar
media (Goodyear A., et al; manuscript in preparation). The
additional antibiotics in NAP-A medium provided increased
selectivity against enteric microflora of multiple mouse strains
(BALB/c, C57BL/6, ICR) as compared to ASH (Goodyear A., et
al; manuscript in preparation).
BALB/c mice (n=9–10 per group) were inoculated with B.
pseudomallei or B. thailandensis orally and quantitative cultures were
done on GI organs 8 weeks after inoculation. Any animal where B.
pseudomallei or B. thailandensis could be recovered from the stomach,
small intestine (SI), cecum or colon on day 60 after inoculation was
considered to be persistently infected. Oral inoculation with 4610
5
and 4610
4 CFU B. pseudomallei yielded similar results, with 89%
and 78% of mice becoming chronically infected, respectively.
Challenge with 4610
3 CFU B. pseudomallei resulted in a 44% rate
of chronic infection, while inoculation with 2.5610
2 CFU B.
pseudomallei resulted in a 10% chronic infection rate (Table 1). The
infectious dose needed to persistently colonize 50% of mice (ID50)
following oral B. pseudomallei infection was determined to be
1.5610
4 CFU according to the Reed-Muench method (Table 1).
Therefore, for most experiments done in this study, an oral
challenge dose of 5610
5 CFU B. pseudomallei strain 1026b was
used, as this dose reliably caused persistent GI infection without
triggering acutely fatal disease.
In contrast to oral B. pseudomallei infection, very high doses of B.
thailandensis were required to cause persistent GI colonization.
Organ plating performed at day 60 following oral infection with B.
thailandensis revealed that 50% of mice were infected with
2.8610
10 CFU, 44% of mice infected with 2.6610
9, and 20% of
mice infected with 2.2610
8 CFU were persistently infected
(Table 1). The ID50 following oral B. thailandensis infection
determined by the Reed Muench method was 1.3610
10 CFU.
This is approximately a 6 log10 increase from the ID50 observed
for B. pseudomallei (Table 1). Additionally, fecal shedding titers
determined at earlier time points were also reduced following oral
inoculation of mice with 2.8610
10 CFU B. thailandensis as
compared to oral infection with 5610
5 CFU B. pseudomallei. For
example, a statistical trend was observed at day 3 (p=0.07) while
titers were significantly reduced in B. thailandensis inoculated mice
at day 14 (p,0.05), 35 (p,0.01) and 56 (p,0.01) (data not shown).
These studies demonstrated therefore that environmental survival
traits alone were not sufficient to explain gastrointestinal
persistence observed following B. pseudomallei infection.
In addition, we investigated the ability of oral challenge with B.
pseudomallei to elicit acutely lethal infection by determining LD50
values according to the Reed-Muench method. LD50 values for
acute disease following oral challenge (ie, mice euthanized on or
Table 1. Persistent gastrointestinal colonization following
oral infection.
B. pseudomallei B. thailandensis
Dose (CFU) % GI Infection Dose (CFU) % GI Infection
3.9610
5 89% (8/9) 2.8610
10 50% (5/10)
4.2610
4 78% (7/9) 2.6610
9 44% (4/9)
3.8610
3 44% (4/9) 2.2610
8 20% (2/10)
2.5610
2 10% (1/10)
ID50
a=1.5 610
4 CFU ID50
a=1.3610
10 CFU
aID50 values calculated according to the Reed-Muench method [101].
doi:10.1371/journal.pone.0037324.t001
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10 per dose), were 1.04610
7 CFU, 7.1610
6 CFU, and
1.9610
3 CFU respectively. From these studies, we observed
mouse strain-specific differences in susceptibility to acute, lethal
infection following oral inoculation. For instance, 129S6/SvEv
mice were highly susceptible to oral infection, similar to results
following respiratory infection [50]. In contrast to previous reports
demonstrating that C57BL/6 mice are more resistant than BALB/
c mice following intranasal, subcutaneous, or oral infection; these
two mouse strains were equally susceptible to oral infection in this
study [45,51,52]. This result may be unique to the combination of
oral infection with B. pseudomallei strain 1026b, as similar results
were observed in a study of acute enteric infection performed with
B. pseudomallei strain 1026b [44]. Following oral infection of
BALB/c mice (n=30) with B. thailandensis strain E264 only one
death was observed 25 days after infection with 2.6610
9 CFU,
while no deaths were observed following oral infection with
2.2610
8 or 2.2610
10 CFU. Thus, oral inoculation with B.
pseudomallei strain 1026b, but not B. thailandensis, reliably produced
either chronic or acute infection in mice, depending on the
challenge dose delivered.
B. pseudomallei is present in all GI organs following oral
inoculation
Using the low-dose oral challenge model, we next investigated
whether there were differences in the location of persistent B.
pseudomallei infection amongst GI organs. BALB/c mice (n=8–9
per group) were inoculated orally with 5610
5 CFU B. pseudomallei
and bacterial burdens in various locations in the GI tract were
determined on days 3, 14 and 56 post-challenge. We observed that
persistent infection could be detected in most mice at all levels of
the GI tract examined, from the stomach through the colon
(Figure 1). Bacteria could be recovered more frequently from the
small intestine, cecum, and colon and at higher titers than from
the stomach.
In mice inoculated orally with Salmonella, Yersinia enterocolitica, or
Shigella dysenteriae, the gallbladder and mesenteric lymph nodes are
often infected [53,54,55,56,57,58]. However, in mice challenged
orally with B. pseudomallei, we found that the mesenteric lymph
nodes or the gall bladder were rarely infected, and if positive were
infected only at a very low level. For example, mesenteric lymph
node infection was found in only 8 of 36 mice, with a mean titer of
9 CFU/organ (data not shown). Likewise, the gall bladder was
infected in only 2 of 26 mice, with a mean titer of 3 CFU/organ
(data not shown).
Given the ability of B. pseudomallei to persistently colonize the GI
tract, we next asked whether infected mice also shed the organism
in their feces. Therefore, we examined fecal shedding of B.
pseudomallei from orally-inoculated mice (5610
5 CFU) over a 60
day period (Figure 2). We found that fecal shedding of B.
pseudomallei could be detected beginning as early as 24 hours
following oral inoculation (data not shown). Remarkably, the level
of fecal shedding remained relatively constant over the next 60
days of observation. The concentration of B. pseudomallei in feces of
persistently infected mice (range=10
2–10
5 CFU/gm feces, aver-
Figure 1. Gastrointestinal bacterial burden following oral B.
pseudomallei challenge. BALB/c mice (n=8–9) were inoculated orally
with 5610
5 CFU B. pseudomallei strain 1026b. On day 3, 14 and 56 after
inoculation, mice were euthanized and organs were processed for
determination of bacterial burden as described in Materials and
Methods. Data are presented as individual log10 CFU/organ values with
bars representing the mean titer for each organ. The limit of detection
was 20 CFU/organ. Data were pooled from two independent experi-
ments.
doi:10.1371/journal.pone.0037324.g001
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3 CFU/gm feces). It should also be noted that persistently
infected mice showed no outward signs of GI infection,
maintaining normal body weight and fecal pellet consistency.
GI infection develops following oral inoculation with
multiple different B. pseudomallei strains
The preceding experiments done with B. pseudomallei strain 1026b
demonstrated a marked propensity to colonize the GI tract and
establish persistent infection following oral inoculation. To deter-
mine whether the ability to establish GI infection was a general
property of B. pseudomallei, or instead reflected a strain-specific
phenomenon, we also subjected mice to oral challenge with 3
additional strains (Bp2671a, Bp2685a, Bp2791a) of B. pseudomallei.
These 3 strainswererandomlyselectedfroma panel of22 clinicalB.
pseudomallei isolates kindly provided by Dr. S. Peacock (now at the
University of Cambridge). In initial experiments, we observed that
oral challenge with a challenge dose of ,5610
5 CFU with the 3
new strains of B. pseudomallei produced a high percentage of acutely
lethal infections, suggesting that these 3 strains were each more
virulent than the 1026b strain (data not shown). Due to the
increased acute lethality of these 3 new strains, colonization of GI
organs at day 3 post infection was used to compare infection with
1026b (see Figure 1) and the 3 new strains. BALB/c mice (n=8–10
per strain) were challenged orally with each of the 3 additional B.
pseudomallei strains (Bp2671a=3.6610
5 CFU; Bp2685a=2.96
10
5 CFU; Bp2719a=3.5610
5 CFU), and the organ bacterial
burden was determined on day 3. We did not observe statistically
significant differences in GI bacterial burdens in mice infected with
strain 1026b compared to the 3 new clinical isolates (Figure 3).
To determine whether lower oral challenge doses could elicit
chronic GI infection with the 3 clinical B. pseudomallei strains,
BALB/c mice (n=3–5 per group) were inoculated with approx-
imately 5610
4 CFU of each of the 3 new B. pseudomallei strains
(Bp2671a=2.0610
4 CFU; Bp2685a=4.8610
4 CFU; Bp2719a=
2.8610
4 CFU). Even a one log reduction in challenge dose still
resulted in rapid lethality with a 58% mortality rate by day 14
post-challenge (data not shown). Determination of bacterial
burden in feces of surviving mice that were challenged orally with
the 3 new clinical strains of B. pseudomallei revealed that 6 of 8 mice
had GI colonization on day 7, while 3 of 5 mice were colonized on
day 14, although the two surviving mice had cleared the GI
infection by day 56 (data not shown). Strain Bp2719a was found to
be especially virulent and p.o. infection with as few as
1.8610
3 CFU resulted in 100% lethality 5 days after infection
(data not shown). Thus, acute challenge studies revealed that all 4
strains of B. pseudomallei were similar in their ability to colonize the
GI tract following oral inoculation. However, the three low-
passage clinical isolates also appeared to be more virulent in vivo
than B. pseudomallei 1026b, as reflected by more rapid spread and
dissemination following oral challenge (See below).
Dissemination to systemic organs following oral B.
pseudomallei inoculation
The liver and the spleen are two of the most frequently affected
visceral organs in humans with melioidosis [3,10,59,60,61]. We
and others have also observed that in mice that survive high-dose
intranasal challenge with B. pseudomallei, death due to disseminated
infection to the liver and spleen often develops over a 30–90 day
period [3,62,63,64]. Therefore, we next investigated whether
disseminated infection to the liver and spleen could develop
following oral inoculation with B. pseudomallei. To address this
question, bacterial burdens in the blood, lung, liver, spleen were
determined 3, 14 and 56 days after low-dose oral challenge of
BALB/c mice (n=8–10) with 5610
5 CFU B. pseudomallei 1026b.
We observed that by day 56 post-challenge, nearly all orally-
inoculated mice had B. pseudomallei lesions in the spleen and liver,
with especially high bacterial burdens in the spleen (Figure 4).
Thus, it appeared that B. pseudomallei could readily disseminate
from the GI tract to the liver and spleen.
We next assessed whether the 3 low-passage B. pseudomallei
strains could also disseminate to the liver and spleen following low-
dose oral inoculation. Mice (n=9–11 per challenge strain) were
inoculated orally (,5610
5 CFU) with each of the three strains
and bacterial burdens were determined in blood, lung, liver, spleen
three days after inoculation. Each of these three strains was able to
cause infection in the blood, lung, liver, and spleen, with bacterial
burdens statistically equivalent to those generated by oral
inoculation with B. pseudomallei strain 1026b; although a trend
towards increased burdens in the liver (p=0.08) and spleen
(p=0.07) were observed following infection with strain Bp2719a as
compared to Bp1026b, when analyzed by a two-tailed Student’s t-
test (Figure S1).
After receiving a low dose oral challenge (,5610
4 CFU) with
strain Bp2671a, Bp2685a or Bp2719a, 6 of 11 mice had grossly
visible splenic lesions, while only 2 of 9 mice inoculated orally with
Bp1026b (5610
5 CFU) had spleen lesions at day 60 post-
challenge. Thus, it was apparent that different B. pseudomallei
strains were capable of disseminating from the GI tract following
oral inoculation.
B. pseudomallei colonizes the stomach following oral
infection
The above experiments demonstrated that B. pseudomallei
persistently colonized all organs of the GI tract. However, we
were interested to determine exactly where the infection was
maintained in the GI tract, including the GI lumen, the GI
mucosa, or submucosal tissues. To address this question,
fluorescent in situ hybridization (FISH) was performed to localize
B. pseudomallei within GI tissues. Preliminary FISH experiments
Figure 2. B. pseudomallei is persistently shed in the feces
following oral inoculation. BALB/c mice (n=10–18 animals per
group) were inoculated orally with 5610
5 CFU. On days 3, 14, 35 and 56
after inoculation, feces were collected and processed for determination
of bacterial burden as described in Materials and Methods. Data are
presented as individual log10 CFU/gram values with bars representing
the mean titer at each time point. The limit of detection was 10–
60 CFU/gram, depending on the number of fecal pellets collected from
each mouse. Data was pooled from two independent experiments.
doi:10.1371/journal.pone.0037324.g002
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demonstrated that the Bpm427 and Bpm975 probes bound to B.
pseudomallei strain 82 (Bp82) but not to B. thailandensis or
endogenous fecal bacteria (data not shown). Additionally, when
Bp82 was added into mixed fecal bacteria, the Eub338 signal from
Bp82 was found to be dim as compared to the signal from fecal
bacteria. Therefore, when the 6-FAM signal from the Eub338
probe was combined with the Cy3 signal from the Bpm427 and
Bpm975 probes, B. pseudomallei typically appeared red in image
overlays rather than yellow (data not shown). For bacterial
localization studies, BALB/c mice were inoculated with
,5610
5 CFU B. pseudomallei strain 1026b and mice were
euthanized 56 days after infection. Tissues were fixed and
hybridized with FISH probes as described in Materials and
Methods. To distinguish B. pseudomallei staining from that of
intestinal debris, tissues were observed at 10006final magnifica-
tion.
Remarkably, FISH staining revealed that the major site of
persistent B. pseudomallei infection following oral inoculation was in
the stomach (Figure 5A). Clusters of bacteria appeared to be
primarily cell-associated in the stomach, and most were found on
the surface of gastric mucosal cells within gastric pits, especially in
the fundus and gastric antrum and pyloric regions of the stomach.
In contrast, B. pseudomallei was much less numerous throughout the
rest of the GI tract, including the small intestine, ileum, cecum,
and large intestine and colon (Fig. 5B–D). In addition, bacteria in
the intestine and colon were typically not associated with mucosal
cells, but were instead found primarily within intestinal luminal
contents. These findings suggested that B. pseudomallei existed in
very different niches in the stomach versus the intestines, being
presumably attached to the mucosa in the stomach and free in the
lumen in the intestines.
Additional FISH studies revealed that all 4 B. pseudomallei isolates
also colonized the stomach (Figure 6). BALB/c mice were
inoculated orally with three additional isolates (Bp2671a=
2.0610
4 CFU; Bp2685a=4.8610
4 CFU; Bp2719a=2.86
10
4 CFU). Organs were harvested from Bp2671a on day 21,
from Bp2685a on day 3, and Bp2719a on day 4 after infection. In
mice infected with Bp1026b, Bp2671a and Bp2719a, B.
pseudomallei organisms were almost exclusively co-localized with
tissue DAPI staining. In contrast, in gastric tissues of Bp2685a
infected mice, the majority of B. pseudomallei organisms were
identified primarily in ingesta in the lumen of the stomach.
Infection with Bp1026b, Bp2671a and Bp2719a resulted in
scattered but concentrated foci of infection, whereas strain
Bp2685a colonization was evenly distributed over larger areas
of the stomach. Similar to Bp1026b, all 3 additional B. pseudomallei
isolates were identified at low levels in the ingesta of the small
intestine and cecum as well as the fecal material in the colon
(Figures S2, S3, S4). Therefore, regardless of the B. pseudomallei
strain used, or the time points that organs were examined, the
stomach was the most heavily colonized organ.
Figure 3. GI colonization occurs following oral inoculation with
multiple B. pseudomallei strains. BALB/c mice (n=9–11 animals
evaluated per bacterial strain) were inoculated orally with Bp2671a
(3.6610
5 CFU); Bp2685a (2.9610
5 CFU); or Bp2719a (3.5610
5 CFU). At
day 3 after infection, organs and feces were processed for determina-
tion of bacterial burden. Data are presented as individual values with
solid bars representing the mean log10 titer. Organ bacterial burdens
are expressed as log10 CFU/organ, and feces titers are graphed as log10
CFU/gram of feces. Dashed bars represent the mean log10 titers from
day 3 Bp1026b bacterial burden determination (Reproduced from
Figure 1 for reference). Data were pooled from 2 independent
experiments. The limit of detection was 20 CFU/organ, and 10–
60 CFU/gram of feces, depending on the number of fecal pellets
collected from each mouse.
doi:10.1371/journal.pone.0037324.g003
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following oral infection, a mosaic of positive 10006 fields from
each stomach was prepared. Positive 10006 fields were then
overlaid over a representative stomach image (Fig. 6E). This
analysis revealed that B. pseudomallei was located primarily in the
pylorus and body of the stomach, and in one case was identified in
the esophagus (Fig. 6E). Similar to Helicobacter pylori infection B.
pseudomallei colonized the pylorus, although B. pseudomallei also
colonized the body of the stomach [65]. Individual localization
mosaic overlays generated using DAPI composite images from
each stomach are shown in Figure S5.
Figure 4. Bacterial dissemination to systemic organs following
oral inoculation with B. pseudomallei. BALB/c mice (n=8–10
animals per time point) were inoculated orally with 5610
5 CFU
Bp1026b. On day 3, 14 and 56 after inoculation mice were euthanized
and organs were processed for determination of bacterial burden. Data
are presented as mean 6 SEM log10 values. Lung, liver and spleen titers
are graphed as CFU/organ, and blood is graphed as CFU/ml. The limit of
detection was 20 CFU/organ, and 10 CFU/ml for blood. Data were
pooled from two independent experiments.
doi:10.1371/journal.pone.0037324.g004
Figure 5. Localization of B. pseudomallei 1026b in gastrointes-
tinal organs following oral infection. (A–D) Stomach (A), small
intestine (B), cecum (C) and colon (D) tissues from mice infected orally
with 5610
5 CFU B. pseudomallei strain 1026b were collected 56 days
after infection. Organs were fixed in 10% NBF and embedded in paraffin
prior to sectioning. FISH was performed on tissue sections as described
in materials and methods. Tissue sections were counterstained with
DAPI (blue) and observed at 10006final magnification. Tissue sections
were hybridized with a eubacterial probe (green), and two B.
pseudomallei specific probes (red). (E–L) Control tissues from uninfected
BALB/c mice were processed as described for B. pseudomallei infected
tissues. To ensure B. pseudomallei probes did not cross react with
enteric bacteria, stomach (E) small intestine (F), cecum (G), and colon (H)
tissues from uninfected BALB/c mice were hybridized with a eubacterial
probe (green), and both B. pseudomallei specific probes (red). To ensure
the FISH procedure resulted in specific probe hybridization, stomach (I),
small intestine (J) cecum (K) and colon (L) tissues from uninfected BALB/
c mice were hybridized with an irrelevant probe (green). Arrows in B–D
indicate the location of B. pseudomallei. In all images the scale bar
represents 10 microns.
doi:10.1371/journal.pone.0037324.g005
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pseudomallei probes to enteric bacteria, GI tissues from uninfected
BALB/c mice were hybridized with the Bpm427, Bpm975 and
Eub338 probes. These experiments demonstrated that the B.
pseudomallei probes did not cross-react with enteric bacteria, while
at the same time the eubacterial probe did bind to enteric bacteria
(Fig. 5E–H). Tissues from uninfected mice were also hybridized
with the irrelevant Non338 probe to ensure that binding of the
FISH probes was sequence specific. While bacterial DAPI signal
was observed in all GI sections, no signal was observed from the
Non338 probe, demonstrating that the FISH procedure resulted in
sequence specific probe binding (Fig. 5I–L).
Focal clusters of intense B. pseudomallei infection were only
identified in the stomach (Fig. 5, Fig S2, S3, S4). Although rare,
submucosal localization of B. pseudomallei within the ileum of the
small intestine was consistently noted in tissues from mice infected
with each of the 4 B. pseudomallei strains tested. In contrast, B.
pseudomallei could not be localized by FISH in cecum or colon
tissue from mice inoculated with either of the 4 B. pseudomallei
strains (data not shown). These results suggested therefore that
following oral inoculation, B. pseudomallei established persistent
infection of the stomach, which resulted in downstream shedding
of bacteria into the small and large intestines, which in contrast to
the stomach appeared not to be colonized by B. pseudomallei.
Mice lack gastrointestinal pathology following enteric B.
pseudomallei infection
Studies were done next to determine if B. pseudomallei enteric
infection was associated with GI lesions. Sections from tissues used
for FISH analysis were analyzed for histopathologic changes.
BALB/c mice (n=32) were inoculated orally with each of 4
different B. pseudomallei strains (Bp1026b=5610
5 CFU;
Bp2671a=2.0610
4 CFU; Bp2685a=4.8610
4 CFU; Bp2719a=
2.8610
4 CFU). Tissues were analyzed from B. pseudomallei infected
mice at multiple time points following infection (Bp1026b days 2,
3, 14, and 56; Bp2671a days 4, 8, and 21; Bp2685a days 2 and 3;
Bp2719a days 4, 8, and 11). Fecal titers of B. pseudomallei were
determined prior to euthanasia to assure that the GI tracts of mice
were heavily colonized (up to 10
6 CFU/gm; data not shown).
Despite the presence of large number of bacteria associated with
the gastric mucosa as demonstrated by FISH, gastric lesions were
not observed in the infected animals (Figure 7, Figure S6).
Moreover, the cecum and colon tissues of infected mice were also
free of lesions. The only lesions noted (in 2 of 32 mice examined)
consisted of mild neutrophil and macrophage infiltrates in the
ileum. In one of these infected animals there was a noticeable
vasculitis and necrosis in the serosa associated with neutrophil and
macrophage infiltration, while necrosis was not observed in the
other animal examined (data not shown).
Ability of B. pseudomallei to infect the GI tract after
challenge by non-oral routes of inoculation
The preceding studies indicated that B. pseudomallei readily
colonized the GI tract following oral inoculation. We therefore
examined whether other routes of inoculation could also produce
chronic enteric infection. Fecal shedding following challenge with
B. pseudomallei strain 1026b was used to survey mice for evidence of
enteric colonization following intranasal (i.n.), intraperitoneal (i.p.),
or subcutaneous (s.c.) inoculation.
Intranasal inoculation resulted in high levels of enteric infection,
whereas inoculation by the s.c. or i.p. routes produced very
different results (Figure 8). For example, none of the mice
inoculated by the s.c. or i.p. routes developed persistent enteric
infection. In contrast, following i.n. inoculation of BALB/c mice
with a very low bacterial challenge dose (approximately 500 CFU
per mouse), 13 of 15 mice (87%) developed persistent enteric
infection. Interestingly, i.n. inoculation also resulted in a higher
percentage of mice with fecal shedding compared to mice
subjected to oral inoculation (87% versus 70%). At present, the
route by which B. pseudomallei colonizes the GI tract following i.n.
inoculation has not been conclusively determined.
The preceding experiments led us to hypothesize that the GI
tract was the primary site of bacterial persistence in mice
inoculated by the oral or i.n. routes. To test this hypothesis, we
inoculated BALB/c mice (n=11) with a low dose (,500 CFU) i.n.
Figure 6. Gastric colonization following oral infection with
different B. pseudomallei isolates. BALB/c mice were infected orally
with B. pseudomallei strain Bp1026b (5610
5 CFU), Bp2671a
(2.0610
4 CFU), Bp2685a (4.8610
4 CFU) or Bp2719a (2.8610
4 CFU).
Stomach tissues were collected from Bp1026b mice 56 days after
infection, Bp2671a mice 21 days after infection, Bp2685a mice 3 days
after infection, and Bp2719a mice 4 days after infection. All tissues were
fixed in 10% NBF and embedded in paraffin before sectioning. FISH was
performed on stomach tissue sections from mice infected with Bp1026b
(A), Bp2671a (B), Bp2685a (C) and Bp2719a (D) as described in materials
and methods. Tissues were counterstained with DAPI (blue), and
observed at 10006final magnification. Tissue sections were hybridized
with a eubacterial probe (green) and two B. pseudomallei specific
probes (red). (E) The location of 10006fields positive for B. pseudomallei
was determined for each B. pseudomallei isolate. Positive 10006fields
are indicated by red (Bp1026b), yellow (Bp2671a), green (Bp2685a) or
blue (Bp2719a) shaded outlines. Outlines were overlaid onto a
representative stomach image created by combining images from a
hematoxylin and eosin stained section. The esophagus (esoph.), body
(corpus) and pylorus of the stomach are labeled for reference. In (A–D)
the scale bar represents 10 microns, and in (E) the scale bar represents
2 mm.
doi:10.1371/journal.pone.0037324.g006
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21, when all mice were clinically asymptomatic. Bacterial burdens
were determined in blood, lung, liver, spleen, kidney, brain,
stomach, small intestine, cecum, colon, and feces, using very
sensitive culture techniques. To increase the sensitivity of bacterial
detection, the entire organ homogenate from each organ was
plated, using large agar plates (limit of detection of 1 CFU/organ).
When bacterial burdens in all organs were compared, significant
differences in bacterial burden were observed between the GI tract
and extra-intestinal organs (lung, liver, spleen, brain and kidney)
(Figure 9). For example, the small intestine, cecum, and colon
each had significantly higher bacterial counts than the lung, liver,
brain, kidney, or spleen (p,0.001). Differences were also observed
between the stomach and extra-intestinal organs, although to a
lesser degree (p,0.05). However, bacterial counts in the lung,
liver, spleen, kidney or brain were not significantly different from
one another, nor were significant differences observed between
bacterial counts in various regions of the GI tract, including the
stomach, small intestine, cecum, and colon. The GI tract was also
much more likely to be infected compared to extra-intestinal
organs. For example, the GI tract was colonized significantly more
often than the lung, brain (p,0.01), spleen (p,0.05), or kidney
(p,0.001) (Figure 9).
Bacterial dissemination occurs more rapidly following
oral inoculation than after s.c. inoculation
Currently, humans are thought to acquire B. pseudomallei
infection primarily via accidental cutaneous inoculation with the
organism [66]. However, it is also possible that other routes of
infection, including oral exposure, may also lead to the develop-
ment of chronic melioidosis and later disseminated infection. To
compare the relative frequency with which chronic disease
developed following cutaneous versus oral inoculation with B.
pseudomallei strain 1026b, mice were inoculated s.c. or orally with
an infectious dose of 5610
4 CFU (0.0026LD50 for s.c. and
0.0046LD50 for oral). The mice were euthanized on day 56 post
infection and bacterial concentrations were determined in blood,
lung, liver, spleen, kidney, brain, stomach, small intestine, cecum,
colon and feces. None of the mice inoculated by the s.c. route had
detectable bacteria in any organ cultured (Table 2). In contrast,
67% of mice inoculated orally had evidence of systemic, extra-
intestinal infection. For example, B. pseudomallei was isolated from
the liver of 6 of 9 mice (p,0.01) and from the spleen of 5 of 9 mice
(p,0.05) inoculated orally. Similar results were also obtained at
day 56 following low dose i.n. inoculation, which also produced
persistent GI colonization (Figure 7). Compared to s.c. inocula-
tion with 5610
4 CFU B. pseudomallei, i.n. inoculation with
,500 CFU B. pseudomallei resulted in liver infection in 6 of 7
mice (p,0.001) and splenic infection in 4 of 7 mice (p,0.05) (data
not shown).
Mice inoculated orally were also much more likely to die from
chronic B. pseudomallei infection than mice inoculated subcutane-
ously. While the day 56 LD50 for s.c. inoculation was
4.9610
6 CFU, the day 56 LD50 for oral inoculation was only
5.9610
4 CFU. These results were consistent therefore with the
idea that bacterial dissemination and chronic disease developed
much more readily following oral inoculation and establishment of
persistent GI colonization with B. pseudomallei strain 1026b.
As noted above, systemic infection was not observed in any of
10 mice subjected to s.c. challenge dose with 5610
4 B. pseudomallei
strain 1026b. However, in 5 mice subjected to much higher
challenge doses of B. pseudomallei by the s.c. route (dose range:
6.6610
6–2.6610
7 CFU), systemic infection did develop in 4 of 5
animals. Notably, all of these mice also developed persistent
cutaneous lesions at the s.c. injection site. When these injection site
lesions were cultured, we found very high bacterial titers, with an
average titer of 3610
7 CFU B. pseudomallei per lesion. Therefore,
these results suggest that efficient dissemination of B. pseudomallei to
other organs may require either a nidus of high-level infection (eg,
cutaneous lesions) or persistent, lower-level infection of the
stomach.
Discussion
Most studies have indicated that melioidosis in humans results
primarily from inhalation or cutaneous inoculation of B.
pseudomallei from the environment [66]. However, melioidosis also
develops in 20–76% of patients with no known exposure to the
Figure 7. Histology in gastrointestinal organs following oral B.
pseudomallei infection. BALB/c mice were in inoculated with
5610
5 CFU B. pseudomallei 1026b. Mice were euthanized 56 days after
infection and tissues were processed and stained with hematoxylin and
eosin as described in methods. Tissues were also collected from
uninfected BALB/c mice as control tissues. Stomach (A), small intestine
(B), cecum (C) and colon (D) images from uninfected BALB/c mice are
shown in the left column. Stomach (E), small intestine (F), cecum (G) and
colon (H) images from B. pseudomallei infected mice are shown in the
right hand column. For stomach images (A, E) the location of each H+E
image within the stomach is indicated by the star on the stomach
outline shown in the bottom left corner of each image. All small
intestine images are from the ileum, and the colon images are from the
proximal colon. Images were captured at 4006final magnification, and
the scale bar on all images represents 25 microns.
doi:10.1371/journal.pone.0037324.g007
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route of infection, such as oral inoculation, may be responsible for
a number of melioidosis cases. In fact, compelling data from
studies done at the turn of the century indicated that B. pseudomallei
was in fact quite infectious in a variety of animal species following
ingestion of the organism [23,24,25,26]. Moreover, recent
epidemiological studies also indicate that oral infection with B.
pseudomallei may be possible [31,37]. Recent studies in mice have
demonstrated that oral infection with B. pseudomallei can cause
acute disease, and results in antibody production and systemic
infection [44,45].
In our present study, we demonstrated that low dose oral
inoculation produced persistent gastric colonization, along with
lower level infection of the intestine and colon, accompanied by
persistent, low-level fecal shedding. The present study also
demonstrated that melioidosis developed readily following low-
dose oral inoculation with multiple different B. pseudomallei strains.
In addition, we showed that B. pseudomallei colonized the GI tract
readily following i.n. inoculation, but not following s.c. or i.p.
inoculation.
The mouse model of enteric infection with B. pseudomallei
exhibits a number of unique features when compared with enteric
infection with other more well-known bacterial pathogens such as
Escherichia coli, Salmonella, and Shigella. For example, the doses of B.
pseudomallei required to infect mice orally (5610
3 to 5610
4 CFU)
are relatively low compared with other enteric pathogens. The
infectious doses reported for most E. coli and Salmonella strains in
mice are in the range of 10
4 to 10
9 CFU [67,68]. In addition, the
level of enteric colonization and fecal shedding with B. pseudomallei
was relatively low compared to other enteric pathogens. Salmonella
and E. coli infection of mice results in fecal shedding titers ranging
from 10
3–10
8 CFU/gram of feces [67,68,69], whereas fecal titers
following B. pseudomallei infection of mice ranged from 10
2–
10
5 CFU/gm feces, with an average titer of 10
3 CFU/gm feces
(see Figure 2).
Equally unique is the fact that B. pseudomallei appeared to
preferentially colonize the stomach and not the lower GI tract.
With Salmonella and enteropathogenic E. coli infection, the ileum
and large intestine are the primary sites of bacterial replication and
invasion [70,71]. The only other well-known example of an enteric
pathogen persistently colonizing the stomach is H. pylori [65].
However, unlike the case with H. pylori infection of the stomach, B.
pseudomallei infection was not associated with any evidence of
gastric inflammation, even after prolonged periods of infection.
Thus, it is likely that B. pseudomallei has evolved resistance
mechanisms to promote survival under harsh gastric conditions,
and also to avoid immune clearance.
Another notable finding was that level of fecal shedding
remained relatively stable for months in infected animals, with
only minor fluctuations over time. In contrast, E. coli, Salmonella or
S. flexneri fecal titers initially increase after inoculation and then
decline to very low levels or disappear as the infection is controlled
by the immune system [67,68,72]. Thus, in the B. pseudomallei
model, the stable level of infection in the GI tract suggests a
Figure 8. B. pseudomallei is persistently shed in feces following i.n. inoculation, but not after s.c. or i.p. inoculation. BALB/c mice were
inoculated with B. pseudomallei using the following route and dose combinations: Oral inoculation (5610
5 CFU) (n=10–18 animals), i.n. inoculation
(,500 CFU) (n=9–17 animals), s.c. inoculation (5610
4 CFU–5610
7 CFU) (n=11–24 animals), or i.p. inoculation (10
6 CFU–10
8 CFU) (n=11–12
animals). On day 3, 14, 35 and 56 after infection, fecal pellets were collected and processed for determination of bacterial burden. Data are graphed as
individual log10 CFU/gram values with bars representing the mean value for each time point. Oral fecal shedding data from figure 2 are reproduced in
this figure for reference. Data were pooled from 2–6 experiments per infection route.
doi:10.1371/journal.pone.0037324.g008
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organism. Moreover, the entire GI tract was infected in B.
pseudomallei inoculated mice. This finding is quite remarkable
considering the very different and inhospitable environments that
exist within the stomach versus the small and large intestine.
It was also apparent that B. pseudomallei was an enteric colonizer
rather than an invasive enteric pathogen. For example, infected
mice did not develop detectable histological lesions at any site in
the intestinal tract following sustained enteric infection. This was
true even in mice subjected to very high challenge doses of B.
pseudomallei, or in very susceptible strains of mice (eg, 129S6/SvEv
mice). In contrast, infection with other enteric pathogens such as
Salmonella, S. dysenteriae, and most E. coli strains produces significant
intestinal pathology [73,74]. Although enterotoxigenic E. coli
infection can cause disease without inducing organ pathology, the
toxins produced by this bacterium also result in diarrhea following
infection [74]. However, mice with enteric B. pseudomallei infection
did not exhibit signs of diarrhea or evidence of weight loss at any
point during infection.
The lack of tissue invasion by B. pseudomallei, in either the
stomach or intestine, likely explains both the lack of a gastric or
intestinal inflammatory response or diarrhea in mice. The gastric
mucosal lining is also where H. pylori colonizes the stomach, and
microscopic niches within the gastric mucosa help H. pylori
bacteria to avoid the low luminal pH [65]. While the pH in the
lumen of the murine stomach is 3, the pH of the mucosa is thought
Figure 9. GI organs colonized more heavily and more frequently than extra-intestinal organs after i.n. challenge. BALB/c mice (n=11
animals per group) were infected via the i.n. route with ,500 CFU Bp1026b. After 21 days, blood, organs and feces were processed for determination
of bacterial burden. (A) Bacterial burden in each organ following low-dose i.n. infection. Data are graphed as individual values with bars representing
the mean log10 titer. Organ titers are plotted as log10 CFU/organ, blood as log10 CFU/ml, and feces as log10 CFU/gram. Statistical differences between
organs were determined using a one-way ANOVA followed by a Tukey’s multiple means test. (***=p,0.001). (B) The percentage of mice with
positive B. pseudomallei cultures from each organ was determined. Statistical differences between percentages in the intestine versus other organs
were determined using a two-tailed Fisher’s exact test. The limit of detection was 1 CFU/organ, 10 CFU/ml for blood, and 10–60 CFU/gram for feces,
depending on the number of fecal pellets collected from each mouse. Both figures were generated by pooling data from 3 independent experiments.
ns=not significant.
doi:10.1371/journal.pone.0037324.g009
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[65,75,76]. B. pseudomallei is known to grow in broth culture at a
pH of 4.5, and can increase the pH of broth media from 4.5 to 7
[77]. In humans the lumen of the human stomach typically has a
pH of 2, but can vary from 2 to 5 [78,79]. B. pseudomallei is known
to survive in saline at a pH of 2 for one day, and has been isolated
from surface water with a pH of 2 [20,80]. Localization of B.
pseudomallei to the stomach is also in agreement with previous case
reports describing gastric ulcers in melioidosis patients [6,37].
While reports of gastric ulcers are rare in melioidosis patients, the
results of this study, as well as original experiments performed by
Whitmore, and oral infection of horses with B. mallei, suggest that
colonization without ulceration may be far more common than
hitherto appreciated [25,81]. Similar to H. pylori colonization,
gastric disease may occur only if B. pseudomallei becomes invasive
[65].
Major risk factors associated with development of melioidosis in
humans include diabetes, alcoholism and chronic kidney disease
[66]. Interestingly, patients with diabetes, alcoholism and chronic
kidney disease also frequently develop gastrointestinal lesions,
particularly gastric lesions. For example, dyspepsia is a common
symptom in diabetics, and diabetic patients are known to develop
gastric ulcers more frequently than non-diabetics [82,83]. In
addition, diabetics can develop gastric ulcers, erosions and severe
acute gastritis without dyspepsia symptoms [84]. Excessive alcohol
consumption is known to directly damage the mucosa of the
esophagus, stomach and small intestine, with exposure to high
concentrations resulting in gastric hemorrhaging [85,86,87].
Excessive alcohol consumption can increase intestinal permeability
and toxin release, leading to increased risk for infection [87,88].
Finally, the association between GI pathology and chronic kidney
disease is well described, and patients with chronic kidney disease
have a higher frequency of upper GI tract lesions than the general
population [89,90,91,92]. Additionally, GI bleeding occurs in 19%
of chronic kidney disease patients, and 61% of these lesions were
localized to the duodenum [93]. Thus, multiple factors associated
with increased risk of disseminated melioidosis are also associated
with increased risk of gastric lesions, which could provide an
avenue for increased dissemination of B. pseudomallei from the
colonized gastric mucosa.
Since enteric colonization with B. pseudomallei did not produce
signs of GI disease in infected mice (and may not in humans as
well), the GI tract could well be considered a sanctuary for
persistent subclinical infection with B. pseudomallei. If the organism
can maintain chronic low level, subclinical enteric infection, it may
persist undetected for months or years. This could then account
for the long lag between initial exposure to the organism and the
development of overt disseminated disease to extra-intestinal sites.
Alternatively, over time low numbers of the organism may
spontaneously enter the bloodstream, leading eventually to organ
seeding and disseminated infection. In this model, the relative risk
of developing disseminated B. pseudomallei infection would increase
with the absolute duration of enteric infection. Although a carrier
state of B. pseudomallei in humans has not been identified thus far,
only throat swabs have been evaluated as a screening test [94,95].
Oral colonization may be overlooked due to multiple technical
challenges involved with processing GI samples, as well as the low
level of B. pseudomallei shedding that may occur. For instance,
previous studies have shown that enteric bacteria from fecal swabs
often outcompete B. pseudomallei when grown on Ashdown’s
medium [31]. In our current study, in order to increase the
sensitivity of organism detection, we had to develop a more
selective Burkholderia culture medium, and we also processed large
volumes of fecal material per mouse at each sampling point. A
similar approach may be difficult in humans, and may require
culture in enrichment broth or concentration prior to analysis.
Alternatively, molecular or fluorescent techniques may be
necessary to identify B. pseudomallei in fecal samples. For example,
molecular techniques were used to demonstrate B. pseudomallei in
the feces of grazing animals [96].
Further studies will be needed to determine how B. pseudomallei
disseminates from the GI tract. In the current study B. pseudomallei
was only rarely isolated from mesenteric lymph nodes, unlike the
case with Salmonella and Y. enterocolitica following GI tract infection
[53,55,56,57]. Furthermore, unlike infection with Salmonella or
Shigella, the gall bladder was rarely colonized with B. pseudomallei
[54,55,58]. Because FISH experiments localized B. pseudomallei to
the stomach, dissemination may be occurring through the gastric
lymph node. This would be in agreement with isolation of B.
pseudomallei from the gastric lymph node of monkeys, and the
gastrohepatic lymph node of pigs [29,97]. Another possibility is
that B. pseudomallei may be disseminating from the ileum, as both B.
pseudomallei and neutrophil recruitment were localized to the ileum
by FISH and histopathology experiments. Although both of these
observations were rare, the identification of both exclusively in the
ileum warrants further investigation.
Studies were also conducted to accurately localize bacteria
immediately after oral inoculation (see Methods). Immediately
following oral inoculation with 5610
5 CFU B. pseudomallei, 21% of
mice had B. pseudomallei in the lungs (limit of detection=4 CFU/
lung). This rate of inadvertent aspiration is much lower than the
89% of mice which ultimately went on to develop disseminated
infection following oral infection with Bp1026b (5610
5 CFU)
(Figure 4). Therefore, the observations in our study are unlikely to
be due solely to aspiration during oral inoculation.
Many of the findings from our mouse model of chronic B.
pseudomallei enteric infection need to be evaluated in humans with
chronic B. pseudomallei infection to determine whether similar rates
and locations of enteric infection also occur in humans. For
example, patients with melioidosis as well as asymptomatic
patients from melioidosis endemic regions could be screened
using sensitive assays combined with endoscopic gastric biopsies
and repeated cultures for detection of low-level fecal shedding of
the organism. If persistent enteric colonization with B. pseudomallei
was found to be prevalent in humans, such a finding would have
Table 2. Systemic and gastrointestinal colonization following
oral or subcutaneous infection.
Challenge Dose=5610
4 CFU
Tissue Oral Subcutaneous p value
a
Blood 44% (4/9) 0% (0/10) p=0.03
Lung 56% (5/9) 0% (0/10) p=0.01
Liver 67% (6/9) 0% (0/10) p=0.003
Spleen 56% (5/9) 0% (0/10) p=0.01
Stomach 56% (5/9) 0% (0/10) p=0.01
SI 78% (7/9) 0% (0/10) p=0.0007
Cecum 78% (7/9) 0% (0/10) p=0.0007
Colon 78% (7/9) 0% (0/10) p=0.0007
Feces 60% (3/5) 0% (0/10) p=0.02
aStatistical differences between oral and subcutaneous infection were
determined by Fisher’s exact test.
doi:10.1371/journal.pone.0037324.t002
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developing public health efforts to control or prevent infection.
In summary, our findings in a mouse model of oral inoculation
with B. pseudomallei indicate clearly that this organism is an efficient
colonizer of the GI tract. Therefore, genes associated with
environmental survival by B. pseudomallei may also be important
for survival in the GI tract [98]. Understanding the mechanisms
that B. pseudomallei uses to sustain persistent enteric colonization
may also yield important insights into how the organism
disseminates from the GI tract to organs such as the spleen, liver,
and central nervous system.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
animal use protocol was approved by the Institutional Animal
Care and Use Committee at Colorado State University (Animal
Welfare Assurance Number A3572-01). Infected animals were
monitored closely three times daily and all efforts were made to
minimize suffering.
Mice
BALB/c and C57BL/6 mice were purchased from Jackson
Laboratories (Bar Harbor, ME). 129S6/SvEv mice were pur-
chased from Taconic Laboratories (Germantown, NY), and ICR
mice were purchased from Harlan Laboratories (Indianapolis, IN).
All mice used in experiments were housed under pathogen-free
conditions in micro-isolator cages and mice were 6–10 weeks of
age at the time of infection. All experiments involving animals
were approved by the Institutional Animal Care and Use
Committee at Colorado State University.
Bacteria
B. pseudomallei strain 1026b (Bp1026b) is a clinical isolate
recovered from the blood of a human patient with septicemic
melioidosis in Thailand [99]. Three low-passage clinical B.
pseudomallei isolates recovered from melioidosis patients in Thai-
land were also used in this study. Strain 2671a (Bp2671a) was
isolated from blood culture, while strain 2685a (Bp2685a) was
isolated from a pus sample, and strain 2719a (Bp2719a) was
isolated from the lungs. In BSL-2 experiments the purM
2 mutant
B. pseudomallei strain 82 (Bp82) derived from Bp1026b was used
[50]. For B. thailandensis experiments, strain E264, an environ-
mental isolate from Thailand was used [100]. All strains were
grown in LB broth (BD Biosciences, San Jose, CA), and stationary
phase cultures were frozen at 280uC in LB broth +20% glycerol
(Fisher Scientific, Pittsburgh, PA). All experiments were performed
with strains from a single freezing event. All procedures involving
B. pseudomallei were performed in a Biosafety Level 3 (BSL3)
facility, in accordance with approved BSL3 and Select Agent
protocols in place at Colorado State University.
Animal infections
Immediately prior to animal inoculation bacterial stocks that
had been frozen in LB broth with 20% glycerol were thawed and
diluted in sterile phosphate buffered saline (PBS) (Sigma-Aldrich,
St. Louis, MO). Infectious doses were determined by plating serial
dilutions of each inoculum on LB agar (BD Biosciences). Oral
(p.o.) inoculations were done using a stainless steel 22 gauge
gavage needle and mice were inoculated using a total volume of
100 ml. For intranasal (i.n.) inoculation, mice were anesthetized
with intraperitoneal (i.p.) injection of ketamine (100 mg/kg)
(Pfizer, New York, NY), and xylazine (10 mg/kg) (Lloyd
Laboratories, Shenandoah, IA). Intranasal inoculations were done
using a volume of 20 ml (10 ml per nostril). Subcutaneous (s.c)
inoculations were done in the right groin and mice were
inoculated with a total volume of 100 ml. Intraperitoneal
inoculation was done by i.p. injection in a total volume of 200 ml.
LD50 values for acute disease (ie, euthanasia required on or
before day 7) were calculated using the Reed-Muench method
[101]. LD50 values in BALB/c used in this study include
3.8610
7 CFU for s.c. inoculation, 1.7610
6 CFU for i.p. inocula-
tion, and as described previously, 9610
2 CFU for i.n. inoculation
[102]. Preliminary experiments were performed to determine if
pulmonary infection occurs following oral infection due to
inadvertent aspiration of bacteria during oral gavage with B.
pseudomallei. Following p.o. inoculation with 5610
5 CFU B.
pseudomallei, BALB/c mice were euthanized two hours after
infection and bacterial burdens were determined in the lungs as
described below (Limit of detection=4 CFU/organ). On average
B. pseudomallei was cultured from the lungs of 3/14 (21%) mice
(data pooled from 3 independent experiments). These results are
similar to previous studies, and due to the potential for aspiration
into the lungs following p.o. inoculation, any mouse succumbing to
acute disease with higher bacterial burdens in the lung than in GI
tissues was excluded from the analysis [44].
Previous studies in our laboratory have demonstrated that
following i.n. inoculation, 40% of the inoculum reaches the lungs
[103]. Briefly, BALB/c mice (n=9) were inoculated i.n. as
described above, and pulmonary bacterial burdens were deter-
mined 3 hours after infection.
Selective medium for isolation of B. pseudomallei from
gastrointestinal tissues
The selective medium used most often for isolation of B.
pseudomallei from clinical samples is Ashdown’s medium (ASH)
[49,104,105]. In preliminary studies we found that ASH failed to
prevent the growth of normal gut commensal bacteria and that
these bacteria in many cases outcompeted B. pseudomallei.
Therefore, to suppress the growth of commensal bacteria we
added norfloxacin, ampicillin, and polymyxin B to ASH media
(NAP-A) for selective isolation of B. pseudomallei from intestinal
contents and feces, based on previously reported media and
antibiotic susceptibility profiles of B. pseudomallei
[104,105,106,107]. To prepare NAP-A medium, we used ASH
medium as the basal medium [49]. Briefly, 4% glycerol, 5 mg/ml
crystal violet (EMD Science, Gibbstown, NJ), 50 mg/ml neutral
red (Sigma-Aldrich), and 4 mg/ml gentamicin (Sigma-Aldrich)
were added to trypticase soy agar (BD Biosciences). After ASH was
autoclaved and cooled to 50–60u, norfloxacin (4 mg/ml) (Sigma-
Aldrich), ampicillin (10 mg/ml) (Sigma-Aldrich) and polymyxin B
(300 units/ml) (Sigma-Aldrich) were added to prepare NAP-A
medium.
Determination of sepsis and organ bacterial burden
For quantitative blood culture, serial 10-fold dilutions of
heparinized blood were diluted in sterile PBS and dilutions were
plated on LB agar plates. Bacterial burden in organ homogenates
was quantitated as described previously, with slight modifications
for the isolation of B. pseudomallei from GI organs [102]. Mice were
euthanized and organs were placed in 4 ml sterile PBS. To ensure
efficient homogenization, the stomach and cecum were cut into
,1–2 cm
2 sections, while small intestine and colon tissues were
cut open longitudinally, and then cut into 2–3 cm lengths. Organs
were homogenized using a Stomacher 80 Biomaster (Seward,
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were prepared in sterile PBS. Lung, liver, spleen, kidney, brain,
gall bladder, and mesenteric lymph node homogenates were
plated on LB agar plates. Stomach, SI, cecum, and colon
homogenates were plated on NAP-A agar (described above). All
agar plates were incubated at 37uC and colonies were counted at
48 hours. The limit of detection in blood was 10 CFU/ml, while
the limit of detection in organ homogenates ranged from 1–
20 CFU/organ.
Isolation of B. pseudomallei from fecal pellets
Fecal pellets were collected by transferring mice from their cage
into a plastic container, where the pellets were collected and
placed in sterile PBS at a concentration of 0.1 gram feces per ml
PBS. Multiple fecal pellets from each mouse (typically 5–6 pellets
per mouse) were homogenized using a Stomacher 80 Biomaster.
Serial dilutions of fecal homogenates were prepared in sterile PBS
and plated on NAP-A agar plates. The limit of bacterial detection
in feces was 10–60 CFU/gram of feces.
Fluorescent in situ hybridization
Fluorescent in situ hybridization (FISH) was performed using
antisense ssDNA probes targeting the bacterial 16S rRNA. B.
pseudomallei specific probes used in this study were designed in our
laboratory. Two probes designated Bpm427 (59-
CCACTCCGGGTATTAGCCAGA-39) (positions 427 to 447)
and Bpm975 (59-CGCCCAACTCTCATCGGG-39) (positions
975 to 992) were identified based on binding regions on the 16S
rRNA gene of B. pseudomallei strain 1026b. Probe specificity was
confirmed in preliminary experiments performed on bacterial
cultures which demonstrated that both Bpm427 and Bpm975
bound to Bp82 [50], and B. mallei ATCC23344 but not to B.
thailandensis E264 or fecal bacteria (data not shown). Consistent
with previous reports, we were unable to develop probes capable
of differentiating B. mallei and B. pseudomallei [108,109,110]. The
previously described Eub338 probe (59-GCTGCCTCCCGTAG-
GAGT-39) which recognizes a conserved sequence present in the
16S rRNA of all bacteria, and the irrelevant Non338 probe (59-
ACTCCTACGGGAGGCAGC-39) containing a sequence com-
plementary to the Eub338 probe were also used [111,112]. All
probes were purchased from Integrated DNA Technologies (San
Diego, CA). Bpm427 and Bpm975 probes were 59 labeled with
Cy3, and Eub338 and Non338 probes were 59 labeled with 6-
FAM.
Tissue fixation was performed as described previously [102].
Briefly, tissues were placed in 10% neutral buffered formalin
(NBF) (Sigma-Aldrich) for 48 hours. The entire small intestine was
collected as a ‘‘Swiss roll’’ and fixed in 10% NBF for 48 hours.
After 48 hours in 10% NBF, all organs were transferred into a
solution of 70% ethanol for 7 days. Tissues were then embedded in
paraffin, and sectioned.
FISH was performed as described previously [113]. Prior to
performing the FISH assay tissue sections were baked for 1 hour at
60uC. Sections were then deparaffinized with HistoclearH
(National Diagnostics, Atlanta, GA) and re-hydrated in solutions
with decreasing ethanol concentration. Sections were post-fixed in
4% paraformaldehyde (Electron Microscopy Science, Hatfield,
PA) in PBS for 15 minutes at room temperature and washed in
PBS. Tissue sections were then permeabilized using one of two
proteinase K digestion (PK) protocols. PCR grade PK was
purchased from Roche (Indianapolis, IN) and was diluted in
10 mM Tris pH 7.5, 5 mM CaCl2, and 0.2% Triton X-100 (All
reagents from Fisher Scientific, Pittsburgh, PA). Preliminary
experiments were performed to determine the optimal digestion
conditions resulting in maximal signal strength from enteric
bacteria, or the maximal digestion procedure which did not alter
tissue morphology. Maximal signal from enteric bacteria was
obtained following digestion in 20 mg/ml PK for 30 minutes at
37uC, as accessed by signal intensity following hybridization with
the Eub338 probe. In contrast, the maximal PK digestion which
did not alter tissue morphology was determined to be 5 mg/ml PK
for 8 minutes at 37uC, as accessed by changes in nuclear
morphology following DAPI staining (data not shown). Therefore,
for identification of B. pseudomallei in ingesta of the stomach and
cecum and fecal material in the colon, sections were digested in
20 mg/ml PK for 30 minutes at 37uC. For localization of B.
pseudomallei in tissues, a separate set of sections was digested in
5 mg/ml PK for 8 minutes at 37uC. All small intestine sections
were digested in 5 mg/ml PK for 8 minutes at 37uC, as
preliminary experiments demonstrated that no increase in signal
from enteric bacteria in the ingesta of the small intestine was
observed regardless of the PK digestion protocol used (data not
shown). Following PK digestion, sections were washed in 30 mM
glycine (Fisher Scientific) to stop proteolysis, followed by a PBS
wash. Next, tissue sections were hybridized with ssDNA probes.
Probes were diluted in hybridization buffer consisting of 46saline
sodium citrate (SSC) (Fisher Scientific), 200 mg/ml dextran sulfate
(Sigma, St. Louis, MO), 20% formamide (Sigma), 0.25 mg/ml
PolyA (Sigma), 0.25 mg/ml salmon sperm DNA (Invitrogen,
Carlsbad, CA), 0.25 mg/ml tRNA (Invitrogen), and 0.56
Dendhart’s solution (Sigma). Slides were hybridized with a cocktail
of the Bpm427, Bpm975 and Eub338 probes each used at a final
concentration of 1 mg/ml, or the Non-338 probe at a final
concentration of 3 mg/ml. Probes were hybridized with tissue
sections in a humidified chamber at 37uC for 24 hours. Following
hybridization sections were washed to remove non-specific probe
binding. Washes included, one 15 minute wash in 16 SSC at
37uC, two 15 minute washes in 16SSC at 55uC, two 15 minute
washes in 0.56 SSC at 55uC, and one 10 minute wash in 0.56
SSC at room temperature. Slides were washed in dH2O at room
temperature for two minutes, air dried, and mounted with Pro-
Long gold containing DAPI (Invitrogen).
Fluorescent microscopy
Following hybridization with FISH probes tissue sections were
observed at 10006 final magnification using an Olympus BX51
fluorescent microscope (Olympus, Center Valley, PA) with DAPI
(Ex. 377/50 nm; Dichroic 409 nm; Em. 477/60 nm), FITC (Ex.
482/35 nm; Dichroic 506 nm; Em. 536/40 nm) and Cy3 (Ex.
531/40 nm; Dichroic 562 nm; Em. 593/40 nm) filter sets
(Semrock, Lake Forest, IL). Photomicrographs were captured
with a DP71 camera using CellSens Entry software version 1.5
(Olympus, Center Valley, PA). Fluorescent overlays were created
by combining individual fluorescent images in Photoshop CS3
software (Adobe, San Jose, CA). When necessary multiple images
were obtained at different focal planes and combined using layer
masks in Photoshop software. All other manipulations were
applied to the images globally. Settings used on images obtained
from tissues hybridized with the Bpm427, Bpm975 and Eub338
probes were determined from images captured from tissues
hybridized with the Non338 probe.
Histological analysis
Tissue processing, staining, and analysis of organ pathology
were performed as described previously [102]. Tissues were
processed as described above for FISH analysis, and lungs were
inflated with 10% NBF via the trachea for 5 minutes prior to
removal, and then placed in 10% NBF for 48 hours. After fixation
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hematoxylin and eosin. Tissues were examined by a veterinary
pathologist (H.B.O.) experienced in mouse pathology. Photomi-
crographs were taken using a Nikon Eclipse 51E microscope and a
Nikon DS-Fi1 camera with a DS-U2 unit and NIS elements F
software and optimized using Photoshop CS3 software (Adobe)
with all changes applied globally.
Statistical analysis
Statistical analyses were done using Prism 5.0 software (Graph
Pad, San Diego, CA). Analyses comparing two groups were done
using a two-tailed Student’s t-test, and analyses comparing more
than two groups were performed using a one-way ANOVA
followed by a Tukey’s multiple means comparison test. Differences
in percentages of positive samples were compared using a two-
tailed Fisher’s exact test. Differences were considered statistically
significant for p,0.05, and statistical trends were considered for
p,0.1.
Supporting Information
Figure S1 Bacterial dissemination to systemic organs
following oral inoculation with 3 B. pseudomallei clinical
isolates. BALB/c mice (n=9–11 animals evaluated per bacterial
strain) were inoculated orally with Bp2671a (3.6610
5 CFU);
Bp2685a (2.9610
5 CFU); or Bp2719a (3.5610
5 CFU). At day 3
after infection, organs were processed for determination of
bacterial burden as described in Materials and Methods. Data
are presented as individual values with solid bars representing the
mean log10 titer. Organ bacterial burdens are expressed as log10
CFU/organ, and blood titers are graphed as log10 CFU/ml.
Dashed bars represent the mean log10 titers from day 3 Bp1026b
bacterial burden determination (Reproduced from Figure 4 for
reference). Data were pooled from 2 independent experiments.
The limit of detection was 20 CFU/organ, and 10 CFU/ml for
blood. Statistical differences were determined between Bp1026b
and each clinical strain using a two tailed Student’s t-test.
(TIF)
Figure S2 Localization of B. pseudomallei 2671a in
gastrointestinal organs following oral infection. Stomach
(A), small intestine (B), cecum (C) and colon (D) tissues from mice
infected orally with 2.0610
4 CFU B. pseudomallei strain 2671a were
collected 21 days after infection. FISH was performed on tissue
sections as described in Materials and Methods. Tissue sections
were counterstained with DAPI (blue) and observed at 10006final
magnification. Tissue sections were hybridized with a eubacterial
probe (green), and two B. pseudomallei specific probes (red). Arrows
in B–D indicate the location of B. pseudomallei. In all images the
scale bar represents 10 microns.
(TIF)
Figure S3 Localization of B. pseudomallei 2685a in
gastrointestinal organs following oral infection. Stomach
(A), small intestine (B), cecum (C) and colon (D) tissues from mice
infected orally with 4.8610
4 CFU B. pseudomallei strain 2685a were
collected 3 days after infection. FISH was performed on tissue
sections as described in Materials and Methods, and sections were
counterstained with DAPI (blue) and observed at 10006 final
magnification. Tissue sections were hybridized with a eubacterial
probe (green), and two B. pseudomallei specific probes (red). Arrows
in C and D indicate the location of B. pseudomallei. In all images the
scale bar represents 10 microns.
(TIF)
Figure S4 Localization of B. pseudomallei 2719a in
gastrointestinal organs following oral infection. Stomach
(A), small intestine (B), cecum (C) and colon (D) tissues from mice
infected orally with 2.8610
4 CFU B. pseudomallei strain 2719a were
collected 4 days after infection. FISH was performed on tissue
sections as described in Materials and Methods, sections were
counterstained with DAPI (blue) and observed at 10006 final
magnification. Tissue sections were hybridized with a eubacterial
probe (green), and two B. pseudomallei specific probes (red). Arrows
in B–D indicate the location of B. pseudomallei. In all images the
scale bar represents 10 microns.
(TIF)
Figure S5 Localization of B. pseudomallei colonization
in the stomach. BALB/c mice were infected orally with B.
pseudomallei strain 1026b (5610
5 CFU), Bp2671a (2.0610
4 CFU),
Bp2685a (4.8610
4 CFU) or Bp2719a (2.8610
4 CFU). Stomach
tissues were collected from Bp1026b mice 56 days after infection,
Bp2671a mice 21 days after infection, Bp2685a mice 3 days after
infection, and Bp2719a mice 4 days after infection. FISH was
performed on stomach tissue sections as described in Materials
and Methods. Tissues were counterstained with DAPI and
observed at 10006 final magnification. Positive 10006 fields
containing B. pseudomallei from mice infected with Bp1026b (A),
Bp2671a (B), Bp2685a (C) or Bp719a (D) are indicated by white
outlines. Outlines are overlaid onto stomach images created by
combining images of DAPI staining obtained from each stomach.
The esophagus (esoph.), body (corpus) and pylorus of the stomach
are labeled for reference. The scale bar in all images represents
2 mm.
(TIF)
Figure S6 Mice lack gastric pathology following oral
infection with different B. pseudomallei isolates. BALB/c
mice were infected orally with B. pseudomallei strain Bp1026b
(5610
5 CFU), Bp2671a (2.0610
4 CFU), Bp2685a (4.8610
4 CFU)
or Bp2719a (2.8610
4 CFU). Stomach tissues were collected from
Bp1026b mice 56 days after infection, Bp2671a mice 21 days after
infection, Bp2685a mice 3 days after infection, and Bp2719a mice
4 days after infection. All tissues were fixed in 10% NBF,
embedded in paraffin and stained with hematoxylin and eosin.
Representative stomach images from Bp1026b (A), Bp2671a (B),
Bp2685a (C), and Bp2719a (D) are shown. The location of each
image within the stomach is indicated by a star on the
representative stomach image in the bottom left corner of each
image. Images were captured at 4006final magnification, and the
scale bar on all images represents 25 microns.
(TIF)
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